We are comparing Akero Therapeutics Inc. (NASDAQ:AKRO) and Bellerophon Therapeutics Inc. (NASDAQ:BLPH) on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akero Therapeutics Inc. | 24 | 0.00 | 8.81M | -3.22 | 0.00 |
| Bellerophon Therapeutics Inc. | 1 | 0.00 | 32.86M | -0.06 | 0.00 |
Table 1 highlights Akero Therapeutics Inc. and Bellerophon Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 demonstrates the return on assets, return on equity and net margins of Akero Therapeutics Inc. and Bellerophon Therapeutics Inc.
| Net Margins | Return on Equity | Return on Assets | |
| Akero Therapeutics Inc. | 36,723,634.85% | 0% | 0% |
| Bellerophon Therapeutics Inc. | 5,758,850,332.98% | -80.6% | -8.6% |
Liquidity
The Current Ratio of Akero Therapeutics Inc. is 29.4 while its Quick Ratio stands at 29.4. The Current Ratio of rival Bellerophon Therapeutics Inc. is 3 and its Quick Ratio is has 3. Akero Therapeutics Inc. is better equipped to clear short and long-term obligations than Bellerophon Therapeutics Inc.
Institutional and Insider Ownership
The shares of both Akero Therapeutics Inc. and Bellerophon Therapeutics Inc. are owned by institutional investors at 48.5% and 54.7% respectively. 17.8% are Akero Therapeutics Inc.’s share held by insiders. On the other hand, insiders held about 4.5% of Bellerophon Therapeutics Inc.’s shares.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Akero Therapeutics Inc. | 5.86% | 27.17% | 0% | 0% | 0% | 32.1% |
| Bellerophon Therapeutics Inc. | -4.54% | 0% | -2.09% | -12.38% | -74.04% | -23.88% |
For the past year Akero Therapeutics Inc. has 32.1% stronger performance while Bellerophon Therapeutics Inc. has -23.88% weaker performance.
Summary
Akero Therapeutics Inc. beats Bellerophon Therapeutics Inc. on 5 of the 9 factors.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
